A systematic review of intravesical bacillus Calmette‐Guérin plus transurethral resection vs transurethral resection alone in Ta and T1 bladder cancer
Open Access
- 1 August 2001
- journal article
- review article
- Published by Wiley in BJU International
- Vol. 88 (3), 209-216
- https://doi.org/10.1046/j.1464-410x.2001.02306.x
Abstract
Objective To assess, in a systematic review, the effectiveness of intravesical bacillus Calmette‐Guérin (BCG) in preventing tumour recurrence in patients with medium/high risk Ta and T1 bladder cancer. Patients and methods An electronic database search of Medline, Embase, DARE, the Cochrane Library, Cancerlit, Healthstar and BIDS was undertaken, plus hand searching of the Proceedings of ASCO, for randomized controlled trials, in any language, comparing transurethral resection (TUR) alone with TUR followed by intravesical BCG in patients with Ta and T1 bladder cancer. Results The search identified 26 publications comparing TUR with TUR + BCG. Six trials were considered acceptable, representing 585 eligible patients, 281 in the TUR‐alone group and 304 in the TUR + BCG group. The major clinical outcome chosen was tumour recurrence. The weighted mean log hazard ratio for the first recurrence, taken across all six trials, was −0.83 (95% confidence interval −0.57 to −1.08, P < 0.001), which is equivalent to a 56% reduction in the hazard, attributable to BCG. The Peto odds ratio for patients recurring at 12 months was 0.3 (95% confidence interval of 0.21–0.43, P < 0.001), significantly favouring BCG therapy. Manageable toxicities associated with intravesical BCG were cystitis (67%), haematuria (23%), fever (25%) and urinary frequency (71%). No BCG‐induced deaths were reported. Conclusion TUR with intravesical BCG provides a significantly better prophylaxis of tumour recurrence in Ta and T1 bladder cancer than TUR alone. Randomized trials are still needed to address the issues of BCG strain, dose and schedule, and to better quantify the effect on progression to invasive disease.Keywords
This publication has 31 references indexed in Scilit:
- Intravesical chemotherapy and immunotherapy for superficial tumors: Basic mechanism of action and future directionUrologic Oncology, 1998
- Guidelines for diagnosis, treatment, and follow-up of bladder cancer: The influence of prognostic factors and the significance of random biopsiesUrologic Oncology, 1998
- A Randomized Multicenter Trial of Adjuvant Therapy in Superficial Bladder Cancer: Transurethral Resection Only Versus Transurethral Resection Plus Mitomycin C Versus Transurethral Resection Plus Bacillus Calmette-GuerinJournal of Urology, 1996
- INTRAVESICAL CHEMOTHERAPY AND IMMUNOTHERAPY: HOW DO WE ASSESS THEIR EFFECTIVENESS AND WHAT ARE THEIR LIMITATIONS AND USES?International Journal of Urology, 1995
- Proposal for changes in cystoscopic follow up of patients with bladder cancer and adjuvant intravesical chemotherapyBMJ, 1994
- Adjuvant Intravesicular Pharmacotherapy for Superficial Bladder CancerJNCI Journal of the National Cancer Institute, 1991
- Prophylactic Maltose Tetrapalmitate and Bacillus Calmette-Guerin Immunotherapy of Recurrent Superficial Bladder Tumors: Preliminary ReportJournal of Urology, 1988
- A prospective randomized trial of maintenance versus nonmaintenance intravesical bacillus Calmette-Guérin therapy of superficial bladder cancer.Journal of Clinical Oncology, 1987
- Bacillus Calmette-Guerin Immunotherapy for Bladder CancerJournal of Urology, 1985
- Intracavitary Bacillus Calmette-guerin in the Treatment of Superficial Bladder TumorsJournal of Urology, 1976